Levamisole

• Description:

  Levamisole ((-) -Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC50=300 μM) and α3β4 (EC50=100 μM) subtype of nAChRs. Orally active[1][2].

• Product Name Alternative:

  (-) -Tetramisole

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  NAChR; Parasite

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/s-minus-levamisole.html

• Concentration:

  10mM

• Purity:

  99.97

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  C12=N[C@@H](C3=CC=CC=C3)CN1CCS2

• Molecular Formula:

  C11H12N2S

• Molecular Weight:

  204.30

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Lewis JA, et al. Levamisole: A Positive Allosteric Modulator for the α3β4 Nicotinic Acetylcholine Receptors Prevents Weight Gain in the CD-1 Mice on a High Fat Diet. Curr Pharm Des. 2017;23 (12) :1869-1872. |[2]Mehta KP, et al. Immunoregulatory treatment for minimal change nephrotic syndrome. Arch Dis Child. 1986;61 (2) :153-158.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Environ Au. 2025 Aug 8.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|EBioMedicine. 2025 Sep:119:105914.|Phytomed Plus. 2025 Aug 23.|Rapid Commun Mass Spectrom. 2023 Feb 15;37 (3) :e9430.|bioRxiv. 2023 Oct 15.|bioRxiv. 2025 Jul 24.|bioRxiv. 2025 Nov 1.|Environ Sci Pollut Res Int. 2023 Jan;30 (5) :12522-12531.|Int J Biol Macromol. 2025 Apr 17;310 (Pt 1) :143312.|J Ethnopharmacol. 2024 Jun 3:118406.

• CAS Number:

  [14769-73-4]